|
|
Article: Side effects of TBWA win include unpleasant Alli account.(TBWA Advertising Inc.)(GlaxoSmithKline Consumer Healthcare Ltd.)
- Article from:
- Advertising Age
- Article date:
- June 8, 2009
- Author:
CopyrightCOPYRIGHT 2009 Crain Communications, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: MARISSA MILEY
TBWA's win last week of $170 million of the GlaxoSmithKline Consumer Healthcare business comes with what a lot of agencies would consider an unpleasant side effect: the chore of marketing a weight-loss drug that can result in anal leakage.
After a review that began in February, Omnicom Group's TBWA is replacing Havas' Arnold, New York, on GSK's roster for its quit-the-habit franchise, which includes Nicorette, NicoDerm CQ and Commitand, perhaps less enviably, FDA-approved, over-the-counter weight-loss aid Alli, which has been on the market since June 2007.
"TBWA has their work cut out for them. This is one of the greatest ...